Prihlásiť sa Zaregistrujte sa zadarmo

Vydané akcie spoločnosti Panbela Therapeutics

Aká je hodnota metriky Vydané akcie spoločnosti Panbela Therapeutics?

Hodnota metriky Vydané akcie spoločnosti Panbela Therapeutics Inc. je 13.434M

Aká je definícia metriky Vydané akcie?



Vydané akcie (Shares outstanding) je počet všetkých akcií spoločnosti alebo finančných aktív, ktoré boli autorizované, vydané a kúpené investormi a sú nimi vlastnené.

Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.

Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.

Vydané akcie spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Panbela Therapeutics

Čomu sa venuje spoločnosť Panbela Therapeutics?

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Firmy s metrikou vydané akcie podobnou spoločnosti Panbela Therapeutics